Jamie Madrigal And The Team – Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
Jamie Madrigal, Scientist at Certara, shared a post by Journal of Thrombosis and Haemostasis on LinkedIn:
”Excited to share that my PhD research on emicizumab was recently published.”
Quoting Journal of Thrombosis and Haemostasis’s post:
”Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions
This study used mathematical modeling and biochemical assays to dissect how emicizumab, a bispecific antibody bridging activated factor IXa and factor X, functions differently from factor VIII. It revealed that high emicizumab levels inhibit factor X activation via tissue factor pathway due to reduced lipid surface binding but enhance factor IXa-dependent activation of factor X on lipid surfaces. The model provides kinetic estimates and explains emicizumab’s mechanism of enhancing coagulation through lipid-surface interactions.
Read this paper here.
Title: Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions
Authors: Jamie Madrigal, Dougald Monroe, Suzanne Sindi, Karin Leiderman”
Stay updated with Hemostasis Today.
-
Nov 15, 2025, 12:24Thomas Reiser: Can AI Keep Up with Thrombosis Specialists?
-
Nov 15, 2025, 12:13Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
-
Nov 15, 2025, 09:32Tushar Pandey: Hounoured to Be Part of Hematocon 2025
-
Nov 15, 2025, 09:11Lisa Murphy invites You to Join Her at Stroke Foundation’s Run4Stroke Marathon
-
Nov 15, 2025, 08:56Ahmed Bennis on Potential Use of P2Y12 Inhibitors as Safer Alternative in Monotherapy
-
Nov 15, 2025, 08:39Marika Nöjd: Donating Blood is An Easy Way to Do Good!
-
Nov 15, 2025, 08:19Joseph Caprini Released His UIP 2025 Session on VTE Recurrence Risk
-
Nov 15, 2025, 07:14Paul Bolaji Invites You to ”Thrombolytic Therapy in Acute Stroke in African Patients” Seminar
-
Nov 15, 2025, 07:03Carla Goulart Peron Explores The Role of Technology and Collaboration in Global Stroke Action